Stocker G, et al. - The effects of dose reduction in obese stage III colon cancer patients undergoing adjuvant chemotherapy were investigated in this analysis. According to chemotherapy dosing at first infusion, survival outcomes and toxicity data of obese, stage III colon cancer patients treated within the phase III PETACC 3 trial comparing leucovorin, 5-FU (LV5FU2) with LV5FU2 plus irinotecan were examined retrospectively. Using Cox regression model, multivariate analyses on relapse free survival (RFS) and overall survival (OS) were conducted to adjust for baseline prognostic factors. Better relapse free survival was seen in fully dosed patients vs those given a reduced dose, so using fully dosed chemotherapy for adjuvant treatment in obese subjects with colon cancer was supported in this trial.